Blood Test (Guardant SHIELD) for Screening of Colorectal Cancer in Underserved Patients

This clinical trial evaluates the use of a blood test (Guardant SHIELD) for colorectal cancer screening. Colorectal cancer is the third leading cancer and cause of death in the United States. Screening may help doctors find colorectal cancer early when it is easier to treat yet nearly a third of all people eligible for screening have never had a screening test performed. Currently, doctors use a stool- based test such as the fecal immunochemical test (FIT) and visual tests such as a colonoscopy. Blood based testing such as Guardant SHIELD, may provide a quick and effective way to screen patients that are hard to reach or with limited access (underserved).

Inclusion Criteria:Women aged 45 years of age and older who are in need of colorectal screeningDo not have a history of cancerAble to read and understand EnglishHave a provider to receive the results of the test and who will follow-up test resultsAble to provide informed consent